Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
about
Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignanciesCurrent Awareness on Comparative and Functional GenomicsComprehensive analysis of HE4 expression in normal and malignant human tissues.Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomasMicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancerMolecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models.Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer.Genomic analysis of epithelial ovarian cancer.Critical molecular abnormalities in high-grade serous carcinoma of the ovary.Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomasMinichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary.Microarray-based gene expression studies in ovarian cancer.From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer.Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival.Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma.Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma.Identification and validation of Kallikrein-ralated peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry.HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.Soluble Mesothelin–related Peptides in the Diagnosis of Malignant Pleural Mesothelioma
P2860
Q27007065-0FAEDAC5-C87A-405A-92E4-9D61AA4D1C49Q27486415-FE6D9654-6637-4E88-A3EC-CC55FE8F2D73Q30440200-741D0300-78E7-4EBB-80DB-760E7DC66419Q30914170-88FC1CA7-507D-4E11-AE5A-137BA3CE44DFQ33506176-EFBB717C-E93B-4577-A224-BE873C3E4FEBQ33508232-7C04F630-1AAA-43BE-B868-BD4FA7DA09D1Q33511864-48250CBB-8ED3-49CD-8969-B921A487A3D3Q33726112-5DD695D6-EA65-4875-959C-F575ECBB9FF4Q34621826-D53058B5-D3D2-420E-9AD6-0B8A362CEA1DQ34632529-358B48D0-7290-4464-809F-2A3E3E8EE8D6Q34984679-711B9121-1C7D-49DC-9693-D85C3621EB98Q35140600-134D19EB-913A-4A3D-B615-A6B5F01AD405Q35683375-C69A6F12-EE1F-41CA-A964-6DC4720A33D0Q36029907-94A6078A-A89E-46C3-9B2C-871EF21529D1Q36091016-2468F651-CE36-474C-85B5-D6461D1C5BFEQ36176058-D4130FCD-6333-4C57-AC8E-839285F53575Q36613726-FF637CB7-4144-43A0-B9F9-405DF7F36570Q37144104-89E8AE81-8207-4AF4-ABCA-5ABADD820ECFQ37232123-42E5D267-4F25-4FA7-9E80-3F8A194BE6A7Q37429878-353BFC57-8A11-4867-B55B-56A7F46EE8BCQ37435376-0D07D784-1686-4847-B5D5-2304C571A8FBQ37661132-E6B242EB-B992-4712-A07D-193A67991EB5Q37832928-5DA3992D-7F89-4910-B0CC-F94A45E4D2A6Q38052927-90ECEA7E-1E83-43E7-9A5D-F101C2074461Q38184632-C8BDEB7F-9CA7-4CF4-88EC-E1044385C566Q43864805-AAF6129E-17D2-4660-B4A6-28AFFF8CC68BQ43901046-793CCCBF-1C7E-44E1-8485-29859CA86B65Q49874891-3EFFE616-5511-4AFC-A4ED-4CA9C615A04DQ51531612-022A7811-91A1-43A3-BF97-402DC7FC67A1Q52651816-6DEF9A03-59A9-48F8-9526-D774BC78516CQ53325005-8F0FF52B-C8EE-4F12-9221-690B3138027AQ54369095-00E9D496-3637-4D02-BFD3-111641893B7FQ55045071-5BDD34B3-E179-484C-9F58-91EB18F520C9Q57554489-E23CEDF0-2FD3-4704-A61E-96F5AFDE824B
P2860
Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Distinction between serous tum ...... bal mRNA expression profiling.
@en
type
label
Distinction between serous tum ...... bal mRNA expression profiling.
@en
prefLabel
Distinction between serous tum ...... bal mRNA expression profiling.
@en
P2093
P1433
P1476
Distinction between serous tum ...... bal mRNA expression profiling.
@en
P2093
Barbara C Vanderhyden
C Blake Gilks
Teri A Longacre
P304
P356
10.1016/J.YGYNO.2004.11.039
P407
P577
2005-03-01T00:00:00Z